GTC Biotherapeutics (fka GTCB)

[DewDiligence]

U.S. ATryn Development Timeline for HD Indication

[These expectations are based on the
slightly-updated guidance on yesterday’s
ThinkEquity webcast (#msg-22963840).]

4Q07: Complete study; report top-line results
1Q08: Complete data analysis
2Q08: Submit BLA
Late 2008/early 2009: FDA decision on BLA

Note: the FDA review period is 6 months or
10 months depending on whether the FDA
grants a priority or a standard review.